MDACC Study No:2007-0091 ( NCT No: NCT00406068)
Title:Open-Label, Multi-Center Study of the Efficacy and Safety of MCC (Mycobacterial Cell Wall-DNA Complex) in the Treatment of Patients with non-muscle invasive (Superficial) Bladder Cancer at High Risk of Progression and Who are Refractory to BCG
Principal Investigator:Jay B. Shah
Treatment Agent:MCC (Mycobacterial cell wall-DNA complex)
Study Status:Terminated
Study Description:The goal of this clinical research study is to study the effect of
mycobacterial cell wall-DNA complex (MCC) on bladder cancer in patients who
have not responded to BCG treatment (in other words, you are "refractory" to
BCG). The safety of the drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Bladder
Phase of Study:Phase III
Treatment Agents:MCC (Mycobacterial cell wall-DNA complex)
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:Patient may be admitted for 23 hour observation after cystoscopy and biopsy at
3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 months
Supported By:Endo Pharmaceuticals Inc
Return Visit:Weekly for 6 weeks, and possible 6 additional weekly instillations.
Evaluations every 3 months with 3 weekly instillation visits. Final
evaluations variable. Early enrollees every 6 months up to 60,
Later enrollees will have fewer evaluations.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jay B. Shah
For Clinical Trial Enrollment:713-792-3250
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults